Baculovirus expression system (BEVS) is well known in the industry and has already been used to create vaccines, such as the FluBlok (Protein Sciences) and Cervarix (Glaxo Smith Kline) vaccines. There are also several animal health vaccines developed by applying BEVS technology. It is an inexpensive method for small or large-scale protein production. We have optimized the expression vectors and the cloning as well as developed facile robust protocols for the creation of baculovirus constructs plus the characterization of expression conditions. We will collaborate with Contract Research Organizations (CROs) that specialize in scale up of protein expression and subsequent purification to produce biosimilars products as well as the subunit and VLPs vaccine products.